

1 - 8 - 02 Attorney Docket No.: V0139/7050

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

ttorney Docket No.	V0139/7050

First Named Inventor or Application Identifier

WARD, Gary E.

Express Mail Label No.

EL844452859US

Date of Deposit

November 9, 2001

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents	ADDRESS Box Patent Application Commissioner for Patents Washington, DC 20231
 □ Fee Transmittal Form (Submit an original, and a duplicate for fee processing) □ Applicant claims small entity status. See 37 CFR 1.27. □ Statement filed in prior application, status still proper and desired. ☑ Specification -Total pages 39 - pages description 1 - pages abstract 4' - pages claims □ Drawing(s) (35 USC 113) - Total sheets □ Informal □ Formal - Total drawings 	8. □ CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix) 9. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. ☒ Computer Readable Form (CRF) b. ☒ Specification Sequence Listing on: i.□ CD-ROM or CD-R (2 copies); or ii. ☒ paper (identical to computer copy) c. ☒ Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 10. □ Assignment Papers/cover sheet & documents(s) 11. □ 37 CFR 3.73(b) Statement (when there is an assignee)
 5. □ Oath or Declaration - Total pages a. □ Newly executed (original or copy) b. □ Copy from a prior application (37 CFR 1 63(d))	□ Power of Attorney 12. □ English Translation of Document (if applicable) 13. □ Information Disclosure Statement/PTO-1449 □ Copies of IDS Citations 14. □ Preliminary Amendment 15. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 16. □ Certified Copy of Priority Document(s) (if foreign priority is claimed) 17. ☒ Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii)
7. ⊠ Application Data Sheet, See 37 CFR 1.76	18. □ Other:

19. If a CONTINUING AP	PLICATION	l check appro	onriate hox and s	unnly the requisite i	nformat	ion below and in		
19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:								
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:, filed on, entitled								
☐ Cancel in this application claims before calculating the filing fee. ☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the								
following:This application is a Continuation Divisional Continuation-in-part (CIP) of prior application No.:, filed on, entitled and now								
Prior application information: Examiner Group Art Unit:								
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.								
	20.	CORRESP	PONDENCE AD	DRESS				
Correspondence address	Correspondence address below							
CUSTOMER NUMBER: 23628								
OR								
ATTORNEY'S NAME	Helen C. Lockhart, Reg. No. 39,248							
FIRM NAME	Wolf, Greenfield & Sacks, P.C.							
ADDRESS	600 Atlantic Avenue							
CITY	Boston		STATE	MA	ZIP	02210		
COUNTRY	USA		TELEPHONE	(617) 720-3500	FAX	(617) 720-2441		
20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED								
NAME		Helen C. Lockhart, Reg. No. 39,248						
SIGNATURE		Helle hoel but						
DATE November 9, 2001								

Express Mail Label No. EL844452859US
Date of Deposit: November 9, 2001

Attorney Docket No: V0139/7050(HCL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Gary E. Ward et al.

Serial No.: Filed:

Not Yet Assigned Herewith

For:

TOXOPLASMA GONDII APICAL MEMBRANE ANTIGEN-1

Examiner:

Unassigned

Art Unit:

Unknown

Box Patent Application Commissioner for Patents Washington, D.C. 20231

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicants enclose herewith a copy of the Sequence Listing and a computer readable diskette. Applicants' attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information.

Respectfully submitted,

Helen C. Lockhart Reg. No. 39,248

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue Boston, MA 02210-2211 (617)720-3500

Docket No. V0139/7050(HCL)

Date: November 9, 2001

X11/09/01

REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(ii)

First Named Inventor WARD, Gary E.

Title TOXOPLASMA GONØII APICAL
MEMBRANE ANTIGEN-1

Attorney Docket No. V0139/7050

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

November 9, 2001

Signatur

Helen C. Lockhart

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**